Drugs & Targets Janssen seeks FDA approval for Imbruvica + rituximab for previously untreated patients with CLL November 15, 2019Vol.45 No.43
Drugs & Targets Canada approves Imbruvica combination for CLL indication November 15, 2019Vol.45 No.43
Drugs & Targets UroGen receives rights to Zalifrelimab for intravesical treatment of urinary tract cancers November 15, 2019Vol.45 No.43
In Brief Ashwani Rajput named director of The Johns Hopkins Kimmel Cancer Center November 15, 2019Vol.45 No.43
In Brief St. Baldrick’s Foundation awards nearly $1.5M in grants to expand children’s clinical trials November 15, 2019Vol.45 No.43
In Brief Moffitt collaborates with VA hospitals to expand clinical cancer research November 15, 2019Vol.45 No.43
White papers by Friends address external controls, progression on immunotherapy, companion diagnostics November 15, 2019Vol.45 No.43By Matthew Bin Han Ong
Conversation with The Cancer Letter Teitell: How immunotherapy became the fourth pillar of cancer care at UCLA November 15, 2019Vol.45 No.43By Paul Goldberg
